CTA1 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Medivir doses first subject in Phase Ib study of oncology drug

CTA1
MIV-818 is a pro-drug designed to selectively treat liver cancers. Credit: humpath.com humpath.com.